BOLD (Boundless Bio) Buyback Yield %: 0.00 (As of Jun. 29, 2026)


BOLD Boundless Bio Inc BOLD
14 GF Score
Price $2.45
! 3 Warning Signs
View Full Analysis

What is Boundless Bio Buyback Yield %?

Boundless Bio BOLD -3.54% 14 Buyback Yield % is 0.00 as of Jun. 29, 2026. GuruFocus rates BOLD with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 742 Biotechnology companies, Boundless Bio ranks worse than 134770.75% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Boundless Bio's current buyback yield was 0.00%.

Boundless Bio Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Boundless Bio's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boundless Bio Buyback Yield % Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00 -143.81 0.00

Boundless Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOLD vs INKT, FLNA, DWTX: Buyback Yield % Comparison

For the Biotechnology subindustry, Boundless Bio's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boundless Bio Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Buyback Yield % falls into.


BOLD
14GF Score
Boundless Bio Inc BOLD
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boundless Bio Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Boundless Bio's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 26.8884
=0.00%

Boundless Bio's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 24.6477
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Boundless Bio (BOLD) has a Buyback Yield % of 0.00 as of Jun. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Boundless Bio and its competitors. According to the industry distribution chart, Boundless Bio ranks #999999 out of 742 companies in the Biotechnology industry.
Is Boundless Bio's Buyback Yield % too high?
Boundless Bio's current Buyback Yield % is 0.00. Based on the distribution chart, Boundless Bio ranks #999999 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's Buyback Yield % compare to INKT and FLNA?
According to the Biotechnology industry distribution chart, Boundless Bio ranks #999999 out of 742 companies for Buyback Yield %. This places Boundless Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Boundless Bio and its competitors. Boundless Bio's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Boundless Bio (BOLD), the current Buyback Yield % is 0.00 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Boundless Bio Business Description

Address 10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score

Get the complete analysis for BOLD

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.45
Price